BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Lifeline Scientific: Trading Update


2/7/2013 11:46:02 AM

February 07, 2013 -- Lifeline Scientific, the medical technology company, issues the following trading update for the year ended 31 December 2012.

Trading in the second half of the year has been strong and as a result we expect to report that revenues for the full year 2012 grew to approximately $30 million (2011: $25.4million).

This performance was driven in large part by a significant increase in revenue growth outside of North America. Most notably we received regulatory approval in Brazil for our full product range during the second quarter of the year and recorded our first commercial sales there, despite being impacted by the ANVISA public worker’s strike between July and September 2012. As previously announced, the Company also benefited from a marked increase in sales of its consumables worldwide, including preservation solutions sales to the NHS, following a successful national UK tender.

Whilst the Company expects to report an increase in turnover, as previously flagged, profit before tax for 2012 is expected to be at a lower level than that reported in 2011. This is primarily due to significant investment to drive and support our geographic expansion in Europe, South America and China, completion of the development phase of the LifePort Liver Transporter product line, and changes in product mix impacting gross margin. The Company also incurred significant legal expenses related to a lawsuit brought in June 2011 against a former vendor and competitor to the Company.

Outlook

Trading in January 2013 has been in line with management expectations and we expect to see continued revenue growth for 2013, driven in particular by another year of solid performance outside of North America.

The Company will announce full year results in April.

Enquiries

Lifeline Scientific, Inc. + 1 847 294 0300

David Kravitz, CEO

Seymour Pierce (Nomad) +44 (0)20 7107 8000

Mark Percy / Sarah Jacobs

FTI Consulting +44 (0)20 7831 3113

Simon Conway / John Dineen

About Lifeline Scientific Inc.

Lifeline Scientific, Inc. is a Chicago-based global medical technology company with regional offices in Brussels and Sao Paulo. The Company’s focus is the development of innovative products that improve transplant outcomes and lower the overall costs of transplantation. Its largest selling clinical products include the LifePort Kidney Transporter, the industry’s leading machine preservation device for kidneys. Devices and consumables for preservation of the liver, pancreas, heart, and lung are in late stage and pre-clinical development.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES